NMS·$1.8B

GENB Generate Biomedicines, Inc.

44SPECULATIVE

CATEGORY BREAKDOWN

GROWTH82
QUALITY0
STABILITY44
VALUATION0
GOVERNANCE93

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

+55.9%
82

> 50% strong

Gross Margin

Revenue retained after direct costs

N/A
0

> 50% strong

Cash Runway

Months of cash at current burn rate

7 months
16

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

-11.1%
100

< 25% strong

Price / Sales

Market cap relative to trailing revenue

57.6x
0

< 3x strong

Rule of 40

Growth rate plus operating margin

-681
0

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

22.6%
89

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+0.0%
100

< 5% ideal

COMPARE GENB WITH…

GENBvs

SCORE ALERT

Get notified when GENB's score changes by 5+ points.

DATA INFO

Last updated: May 4, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.